This is a passive scheme based on certain rules. The strategy does not take into account the valuations of the stocks, which are high currently. The product is launched in the ETF format. Most smart beta ETFs in India suffer from low liquidity on the stock exchanges. Also, smart-beta funds are yet to develop a long track record. Therefore, it may be hard to assess how such schemes would perform across market cycles. … [Read more...] about ICICI Pru Alpha Low Vol 30 ETF NFO: Should you invest?
The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA)Vardenafil Hydrochloride tablets in the strengths of 2.5 mg, 5 mg, 10 mg and 20 mg, Alembic Pharmaceuticals said in a BSE filing. … [Read more...] about Alembic Pharmaceuticals gets USFDA nod for erectile dysfunction drug
- Phase 3 (2014 to 2019) – Successful domestic acquisitions: Having learned from its mistakes made in the preceding phase of international acquisitions, Pidilite resumed its focus on frequently acquiring smaller domestic competitors in its core business. For example, Bluecoat has been acquired for ~Rs 260 crores (6% of FY14-19 operating cash flows) and Suparshva for an undisclosed consideration. These acquisitions have turned out to be substantially RoCE accretive for Pidilite. The firm has also deployed ~Rs 300 crores over FY14-19 (~7% of operating cash flows and ~2-3% of capital employed over this period) to acquire businesses in adjacent categories (CIPY – floor coatings; Nina and Percept – waterproofing contractors) and has formed JVs with MNCs like ICA for niche products like wood finishes. These businesses have shown significant improvement in financial performance post-acquisition. In addition to disciplined capital … [Read more...] about Saurabh Mukherjea’s investment mantra to navigate through a crisis: Part-2
Link PharmachemStandalone Quarterly Resultsin Rs. Cr.Jun'20Mar'20Jun'19Net Sales/Income from operations5.105.815.58Other Operating Income------Total Income From Operations5.105.815.58EXPENDITUREConsumption of Raw Materials1.281.051.54Purchase of Traded Goods------Increase/Decrease in Stocks-0.100.520.67Power & Fuel------Employees Cost188.8.131.52Depreciation0.230.260.22Excise Duty------Admin. And Selling Expenses------R & D Expenses------Provisions And Contingencies------Exp. Capitalised------Other Expenses2.012.231.49P/L Before Other Inc. , Int., Excpt. Items & Tax0.550.640.45Other Income0.000.10--P/L Before Int., Excpt. Items & Tax0.550.730.45Interest0.100.110.10P/L Before Exceptional Items & Tax0.440.620.36Exceptional Items------P/L Before Tax0.440.620.36Tax0.120.330.10P/L After Tax from Ordinary Activities0.320.290.25Prior Year Adjustments------Extra Ordinary Items------Net Profit/(Loss) For the Period0.320.290.25Equity Share Capital4.444.444.44Reserves … [Read more...] about Link Pharmachem Standalone June 2020 Net Sales at Rs 5.10 crore, down 8.53% Y-o-Y
AtishayStandalone Quarterly Resultsin Rs. Cr.Jun'20Mar'20Jun'19Net Sales/Income from operations6.396.795.12Other Operating Income------Total Income From Operations6.396.795.12EXPENDITUREConsumption of Raw Materials4.044.562.65Purchase of Traded Goods0.030.03--Increase/Decrease in Stocks-0.020.030.19Power & Fuel------Employees Cost0.701.121.25Depreciation0.410.530.31Excise Duty------Admin. And Selling Expenses------R & D Expenses------Provisions And Contingencies------Exp. Capitalised------Other Expenses0.320.840.48P/L Before Other Inc. , Int., Excpt. Items & Tax0.91-0.310.24Other Income0.070.530.35P/L Before Int., Excpt. Items & Tax0.980.220.59Interest0.140.090.07P/L Before Exceptional Items & Tax0.850.130.52Exceptional Items------P/L Before Tax0.850.130.52Tax0.27-0.320.11P/L After Tax from Ordinary Activities0.580.450.41Prior Year Adjustments------Extra Ordinary Items------Net Profit/(Loss) For the Period0.580.450.41Equity Share Capital10.9810.9810.98Reserves … [Read more...] about Atishay Standalone June 2020 Net Sales at Rs 6.39 crore, up 24.83% Y-o-Y